News
Hosted on MSN13d
Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders WaryEli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase ...
Cigna's pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.
Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...
The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...
6don MSN
Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...
People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo Nordisk’s ...
The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.
Novo Nordisk A/S is selling its blockbuster weight-loss drug Wegovy to new patients at $199 for the first month as easy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback